Hologic (NASDAQ:HOLX) Issues Q2 2025 Earnings Guidance

Hologic (NASDAQ:HOLX) updated its second quarter 2025 earnings guidance on Wednesday. The company provided EPS guidance of 1.000-1.030 for the period, compared to the consensus EPS estimate of 1.040. The company issued revenue guidance of $995.0 million-$1.0 billion, compared to the consensus revenue estimate of $1.0 billion. Hologic also updated its FY 2025 guidance to 4.250-4.350 EPS.

Hologic Stock Performance

Shares of NASDAQ:HOLX traded down $6.35 during trading on Thursday, hitting $66.45. 3,652,659 shares of the stock traded hands, compared to its average volume of 2,341,251. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The company has a market cap of $15.00 billion, a price-to-earnings ratio of 19.96, a P/E/G ratio of 2.35 and a beta of 0.97. The company has a fifty day moving average price of $72.91 and a two-hundred day moving average price of $77.95. Hologic has a 52-week low of $65.87 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. As a group, equities analysts predict that Hologic will post 4.28 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on HOLX shares. Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a report on Monday. UBS Group lifted their target price on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. BNP Paribas raised shares of Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Wolfe Research assumed coverage on shares of Hologic in a research note on Friday, December 13th. They set a “peer perform” rating on the stock. Finally, Jefferies Financial Group assumed coverage on shares of Hologic in a research note on Tuesday, December 10th. They set a “hold” rating and a $85.00 target price on the stock. Nine equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $86.46.

Insider Buying and Selling at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.88% of the stock is currently owned by corporate insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.